Emmanuelle Trombe represents pharmaceutical, medical device and bio-pharmaceutical companies globally in transactional matters in relation to M&A and divestitures, joint ventures and strategic partnerings, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters. She also advises venture capital funds and bio-pharmaceutical companies in connection with a broad range of financing activities.

Show More


  • Represented Innate Pharma on its global co-development and commercialization agreement with AstraZeneca for IPH2201, a novel antibody in Phase II development for the treatment of cancer
  • Represented Servier in connection with its strategic partnership with Intarcia Therapeutics. The transaction is one of the largest biotechnology partnership agreements outside the United States
  • Represented Pierre Fabre on its collaboration and licensing agreement with Array Biopharma for the development and commercialization of two novel oncology products, Binimetinib and Encorafenib

Show More


  • Chambers Europe 2014 – 2018, Band 1, Pharma/Life Sciences (France): Emmanuelle is recommended for her expertise in “commercial, corporate and regulatory matters in the industry of healthcare and medical devices.” She was described as: “very knowledgeable in pharma, bio-technology and licensing agreements. She is also very business-oriented.”
  • The Legal 500 EMEA 2017, Healthcare and Life Sciences-France
  • The Best Lawyers in France 2019, Biotechnology and Life Sciences Practice


  • Médecins sans Frontières, regularly provides contractual advice to this international humanitarian medical association


École Supérieure de Commerce de Paris (ESCP)
University of Paris II Panthéon-Assas, LLM (Maîtrise), Tax and Commercial Law
Complutense University of Madrid, Master AMSEC


Show More